Jazz Pharmaceuticals plc — Form 8-K

Jazz Pharmaceuticals reported Q3 2026 revenues of $1.243B (+10% YoY), raising full-year 2026 total revenue guidance from $4.6-4.75B to $4.775-4.85B. Key drivers: Xywav grew 12% YoY to $483M in Q3 (425 net patient adds); Ziihera generated $21M in Q3 after FDA approval on August 25, 2026 for first-line HER2+ gastroesophageal adenocarcinoma; Zepzelca grew 32% YoY to $104M. Jazz closed acquisition of Actio Biosciences in September 2026, acquiring ABS-1230 (JZP6979) for rare KCNT1-related epilepsy, with $754M in-process R&D expense recorded. Company generated $1.3B in operating cash flow YTD; issued $1.25B exchangeable notes and repurchased $225M shares; debt stands at $5.6B with $2.9B cash/investments.